1. THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

3. Introduction

4. Introduction (cont)

5. Liquid Biopsy

6. Tissue-Based vs Liquid Biopsy RAS Analysis: Pros and Cons

7. Testing for Circulating Tumor DNA

8. Role of RAS Testing in the Treatment of mCRC

9. Case Introduction

10. Molecular Features to Be Considered When Selecting First-Line Therapy

11. Treatment of CRC Metastatic Disease: ESMO 2016, Biomarkers Recommended for Routine Assessment

12. Tissue-Based vs Plasma Biomarker Testing

13. Case Discussion: Assessment of Biomarkers Before First-Line Treatment Selection

14. Case Discussion: First-Line Treatment

15. Molecular Considerations at Progression to First-Line Anti-EGFR Therapy

16. Case Discussion: Second-Line Treatment

17. Molecular Considerations at Progression to Second-Line Therapy

18. Retest for RAS?

19. Anti-EGFR Rechallenge Strategy

20. How Can Liquid Biopsy-Based Biomarker Testing Potentially Guide Treatment Decisions After Anti-EGFR Therapy? Ongoing Trials

21. Rechallenge With Anti-EGFR Therapy: FIRE-4 Study

22. HERACLES Trial

23. Continuation of EGFR Therapy While Switching Chemotherapy in RAS WT mCRC

24. Continued Cetuximab for Unresectable KRAS WT mCRC at Progression During First-line Cetuximab-based Chemotherapy

25. Case Discussion: Third-Line Treatment

26. Extended Gene Mutation by NGS in the CAPRI-GOIM Trial

27. Concluding Remarks

28. Abbreviations

29. Abbreviations (cont)

30. Abbreviations (cont)